Back to top
more

Blueprint Medicines (BPMC)

(Delayed Data from NSDQ)

$105.56 USD

105.56
631,490

-0.80 (-0.75%)

Updated May 31, 2024 04:00 PM ET

After-Market: $105.54 -0.02 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for BPMC

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

1 item in cart

View Cart/Checkout

Blueprint Medicines Corporation [BPMC]

Reports for Purchase

Showing records 421 - 440 ( 510 total )

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 421

10/09/2018

Industry Report

Pages: 7

Biotechnology -ESMO 2018 Abstract Roundup for Covered Companies

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 422

10/08/2018

Company Report

Pages: 7

Data Releases at ATA Meeting Show Comparability between RET Inhibitors

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 423

10/08/2018

Daily Note

Pages: 6

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 424

09/21/2018

Industry Report

Pages: 9

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 425

08/10/2018

Industry Report

Pages: 8

HEALTHCARE: The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 426

08/02/2018

Company Report

Pages: 8

Q2 Financials; Potential NDA Submission for 4L GIST in 1H19

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 427

07/27/2018

Industry Report

Pages: 8

HEALTHCARE -The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 428

06/19/2018

Daily Note

Pages: 5

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 10.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 429

06/19/2018

Daily Note

Pages: 6

EHA Update; Avapritinib, ORR And Durability Improves in Advanced SM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 430

06/04/2018

Industry Report

Pages: 8

Biotechnology -ASCO Presentations Roundup for Covered Companies: Part 1

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 431

05/25/2018

Industry Report

Pages: 8

HEALTHCARE - The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 432

05/17/2018

Industry Report

Pages: 6

Biotechnology -ASCO Abstract Roundup

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 433

05/17/2018

Company Report

Pages: 9

ASCO Abstracts Released; Decreasing Our PT with Heightened Competition

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 434

05/03/2018

Daily Note

Pages: 10

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 435

05/03/2018

Company Report

Pages: 8

Q1 Financials; First NDA Submission for Avapritinib Set for 1H19

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 436

04/25/2018

Daily Note

Pages: 17

AACR Roundup for Covered Companies

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 50.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 437

04/16/2018

Company Report

Pages: 10

BLU-667 Data Shaping up Well, Hints of Durable Treatment Benefit Emerging

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 438

04/16/2018

Daily Note

Pages: 7

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 439

04/13/2018

Industry Report

Pages: 8

HEALTHCARE - The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Blueprint Medicines Corporation

Industry: Medical - Biomedical and Genetics

Record: 440

04/06/2018

Industry Report

Pages: 8

HEALTHCARE -The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party